3 Stocks Pushing The Drugs Industry Lower

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 60 points (0.4%) at 16,517 as of Tuesday, April 1, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,859 issues advancing vs. 1,154 declining with 141 unchanged.

The Drugs industry currently sits up 0.5% versus the S&P 500, which is up 0.4%. A company within the industry that fell today was Novo Nordisk A/S ( NVO), up 0.8%. Top gainers within the industry include Regeneron Pharmaceuticals ( REGN), up 2.6%, Alexion Pharmaceuticals ( ALXN), up 1.6%, Actavis ( ACT), up 1.5%, Valeant Pharmaceuticals International ( VRX), up 1.2% and AstraZeneca ( AZN), up 0.7%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3. Bristol-Myers Squibb Company ( BMY) is one of the companies pushing the Drugs industry lower today. As of noon trading, Bristol-Myers Squibb Company is down $0.55 (-1.1%) to $51.40 on light volume. Thus far, 3.3 million shares of Bristol-Myers Squibb Company exchanged hands as compared to its average daily volume of 9.2 million shares. The stock has ranged in price between $51.23-$52.39 after having opened the day at $52.23 as compared to the previous trading day's close of $51.95.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. Bristol-Myers Squibb Company has a market cap of $85.9 billion and is part of the health care sector. Shares are down 2.3% year-to-date as of the close of trading on Monday. Currently there are 10 analysts that rate Bristol-Myers Squibb Company a buy, 2 analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Bristol-Myers Squibb Company as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, good cash flow from operations, solid stock price performance, largely solid financial position with reasonable debt levels by most measures and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Bristol-Myers Squibb Company Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Merck ( MRK) is down $0.52 (-0.9%) to $56.25 on light volume. Thus far, 3.6 million shares of Merck exchanged hands as compared to its average daily volume of 12.7 million shares. The stock has ranged in price between $56.02-$56.84 after having opened the day at $56.65 as compared to the previous trading day's close of $56.77.

Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products worldwide. Merck has a market cap of $164.6 billion and is part of the health care sector. Shares are up 13.4% year-to-date as of the close of trading on Monday. Currently there are 6 analysts that rate Merck a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Merck as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Merck Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Pfizer ( PFE) is down $0.24 (-0.8%) to $31.88 on average volume. Thus far, 11.3 million shares of Pfizer exchanged hands as compared to its average daily volume of 26.8 million shares. The stock has ranged in price between $31.80-$32.25 after having opened the day at $31.93 as compared to the previous trading day's close of $32.12.

Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. Its product portfolio includes medicines and vaccines, as well as various consumer healthcare products. Pfizer has a market cap of $203.8 billion and is part of the health care sector. Shares are up 4.9% year-to-date as of the close of trading on Monday. Currently there are 7 analysts that rate Pfizer a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Pfizer as a buy. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, increase in stock price during the past year and good cash flow from operations. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Pfizer Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

Flashback Friday: The Market Movers

Flashback Friday: The Market Movers